GlassScriptPhysician profile
John N Defranco
NPI 1629008164
$5,938.99
in general payments reported to CMS, 2019-2025
47 companies · $589 in 2025
The $589 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $972 · 2020: $883 · 2021: $883 · 2022: $896 · 2023: $766 · 2024: $950 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,305.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,304.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $651.41 | 2019-2025 | Erleada, Akeega |
| Astellas Pharma US INC | $626.64 | 2019-2025 | Xtandi |
| Abbvie INC. | $483.98 | 2019-2025 | Lupron Depot |
| Sumitomo Pharma America, INC. | $470.29 | 2023-2025 | Orgovyx, Gemtesa |
| Dendreon Pharmaceuticals LLC | $429.57 | 2020-2024 | Provenge |
| Antares Pharma, INC. | $280.86 | 2019-2025 | Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $264.96 | 2019-2025 | |
| Boston Scientific Corporation | $263.09 | 2019-2024 | Spaceoar Vue System - 10ml |
| Pfizer INC. | $255.50 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $199.17 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Olympus America INC. | $143.76 | 2024-2025 | Itind System |
| Srs Medical Systems, INC. | $143.48 | 2021 | |
| Allergan, INC. | $141.03 | 2019-2021 | |
| Travere Therapeutics, INC. | $120.47 | 2019-2022 | |
| Ambu INC. | $114.68 | 2020-2021 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Defranco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.